source
- RA Capital backs Oak Hill Bio's Nasdaq debut via $175 million SPAC mergerRA Capital announced that its SPAC, Research Alliance Corporation III, will merge with Oak Hill Bio, creating a new Nasdaq-listed rare-disease company. The combined entity will start with $175 mil…
- Argenx to acquire Forte Biosciences for $2.2 billion, securing phase-2 vitiligo antibody FB102Argenx announced it will buy Forte Biosciences for $2.2 billion, gaining access to FB102, an anti‑CD122 antibody currently in phase‑2 trials for vitiligo and celiac disease. In a recent phase 1b s…